KN035

DRUG6 trials

Sponsors

3D Medicines (Sichuan) Co., Ltd., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, RenJi Hospital

Conditions

Advanced or Metastatic Solid TumorsHER2-positive Breast CancerMultiple Primary NeoplasmSolid TumorSolid Tumors

Phase 1

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

CompletedNCT02827968

3D Medicines (Sichuan) Co., Ltd.Solid Tumors

Start: 2017-01-13End: 2020-12-31Updated: 2021-06-02

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

CompletedNCT03101488

3D Medicines (Sichuan) Co., Ltd.Solid Tumors

Start: 2017-03-21End: 2020-08-25Updated: 2022-03-03

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

CompletedNCT03248843

3D Medicines (Sichuan) Co., Ltd.Advanced or Metastatic Solid Tumors

Start: 2017-09-15End: 2020-03-31Updated: 2022-02-08

Phase 2

KN035 for dMMR/MSI-H Advanced Solid Tumors

RecruitingNCT03667170

3D Medicines (Sichuan) Co., Ltd.Solid Tumor

Start: 2018-08-22End: 2026-12-30Target: 200Updated: 2026-03-25

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHER2-positive Breast Cancer

Start: 2019-09-01End: 2022-01-01Target: 59Updated: 2019-07-26

KN035 in Patients With Advanced Multiple Primary Tumors

RenJi HospitalMultiple Primary Neoplasm

Start: 2019-03-26End: 2021-08-31Target: 20Updated: 2019-12-02

Related Papers

Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors

The Oncologist2024-07-092 citations

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.

2022-08-0624 citations

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.

2021-06-21101 citations

Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.

Journal of Clinical Oncology2020-05-205 citations

Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.

Journal of Clinical Oncology2019-05-2013 citations

Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-207 citations

Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA

Annals of Oncology2018-10-0115 citations

A phase I, open, multiple dose, dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of KN035 (anti-PD-L1 antibody) administered in subcutaneous injection as a single agent to Chinese subjects with advanced solid tumors.

Journal of Clinical Oncology2018-05-202 citations